- Home
- ARWR vs PK Comparison
ARWR vs PK Comparison
Compare ARWR & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARWR
- PK
- Stock Information
- Founded
- ARWR 2003
- PK 1946
- Country
- ARWR United States
- PK United States
- Employees
- ARWR N/A
- PK N/A
- Industry
- ARWR Biotechnology: Pharmaceutical Preparations
- PK Real Estate Investment Trusts
- Sector
- ARWR Health Care
- PK Real Estate
- Exchange
- ARWR Nasdaq
- PK Nasdaq
- Market Cap
- ARWR 1.7B
- PK 2.5B
- IPO Year
- ARWR 1993
- PK N/A
- Fundamental
- Price
- ARWR $12.21
- PK $10.76
- Analyst Decision
- ARWR Buy
- PK Buy
- Analyst Count
- ARWR 11
- PK 11
- Target Price
- ARWR $41.44
- PK $17.95
- AVG Volume (30 Days)
- ARWR 1.7M
- PK 4.4M
- Earning Date
- ARWR 05-08-2025
- PK 05-05-2025
- Dividend Yield
- ARWR N/A
- PK 13.02%
- EPS Growth
- ARWR N/A
- PK 129.54
- EPS
- ARWR N/A
- PK 1.01
- Revenue
- ARWR $2,500,000.00
- PK $2,611,000,000.00
- Revenue This Year
- ARWR $4,380.43
- PK $3.56
- Revenue Next Year
- ARWR $58.72
- PK $3.55
- P/E Ratio
- ARWR N/A
- PK $10.64
- Revenue Growth
- ARWR N/A
- PK N/A
- 52 Week Low
- ARWR $12.14
- PK $10.46
- 52 Week High
- ARWR $30.41
- PK $17.87
- Technical
- Relative Strength Index (RSI)
- ARWR 25.33
- PK 33.37
- Support Level
- ARWR $14.69
- PK $10.46
- Resistance Level
- ARWR $15.65
- PK $11.65
- Average True Range (ATR)
- ARWR 0.73
- PK 0.35
- MACD
- ARWR -0.17
- PK -0.03
- Stochastic Oscillator
- ARWR 1.75
- PK 22.01
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.